ADVANCED DISCOVERY
PLATFORM

Microviable Therapeutics is developing novel technologies and next generation biotherapeutic products by harnessing the treasure of the human microbiota generating innovative solutions that enable to address unmet challenges in human diseases.

Breakthrough Technology

Our proprietary breakthrough technology enables us to isolate and purify the microbiota and to perform long-term storage of viable microbiota, without disrupting its original identity. We can now obtain hundreds of doses of viable non-propagated microbiota from a single donor, that can be stored for long-term to be used as a therapeutic product.

We have created a Microbiota Library with hundreds of purified microbiota samples from validated healthy donors, and tailored with our bioinformatics capabilities, is leading up the concept of using the whole microbiota as a therapeutic product for specific diseases. Colonization, competitive exclusion and immune modulation are key to restore the altered microbiome and that can only be achieved by the complete microbiota.

Proprietary Bacterial Culture Collection

In parallel, the microbiota library is feeding up our Discovery Pipeline to isolate and characterize golden microbial strains enabling to develop live biotherapeutic products (LBPs) based on rationally designed microbial communities.

Our high throughput pipeline for culturomics provided us a vast variety of bacterial species including strict anaerobes, while our latest approach on targeted-culturomics is allowing us to isolate specific microbes of interest.

Microviable Therapeutics has one of the largest and diverse proprietary bacterial culture collections with thousands of isolates belonging to hundreds of different species.

Proprietary Bacterial Culture Collection

In parallel, the microbiota library is feeding up our Discovery Pipeline to isolate and characterize golden microbial strains enabling to develop live biotherapeutic products (LBPs) based on rationally designed microbial communities.

Our high throughput pipeline for culturomics provided us a vast variety of bacterial species including strict anaerobes, while our latest approach on targeted-culturomics is allowing us to isolate specific microbes of interest.

Microviable Therapeutics has one of the largest and diverse proprietary bacterial culture collections with thousands of isolates belonging to hundreds of different species.

International Perspective

The stablished partnerships with physicians across different countries is enabling us to obtain clinically relevant datasets from observational studies to understand the microbiota and metabolites perturbation existing in gut, skin and neurological disorders.

Microviable Therapeutics is building up a fundamental Intellectual Property portfolio in the human microbiota field. Our IP portfolio includes several issued patents licensed with exclusive rights to Microviable as well as other pending applications ongoing. Our patents provide coverage up to 2036 on products to collect and transport the microbiota in anaerobic conditions, and up to 2041 on methods to isolate and store the microbiota in viable conditions keeping its original identity. Our patents also provide coverage on methods to selectively isolate desired bacterial species from the microbiota. This IP portfolio is enhancing Microviable Therapeutics strategic development towards the clinical practice enabling us to support our internal research programs advancing microbiota-based biotherapeutic products.

Patent No. Title Applicant Issue date
ES201630176 Device for microbiota collection and transport in anaerobic condition CSIC July 10, 2018
EP19383077 Tools and methods to detect and isolate colibactin producing bacteria CSIC Pending
Trade Secret (ref.: 2203) Methods for long-term preservation of gut microbiota in viable conditions CSIC-MVT April 13, 2021
Trade mark GutAlive® Microviable Therapeutics January 23, 2018
Trade mark Microviable Therapeutics Microviable Therapeutics April 26, 2017

Patent No.: ES201630176

Title: Device for microbiota collection and transport in anaerobic condition

Applicant: CSIC

Issue date: July 10, 2018

Patent No.: EP19383077

Title: Tools and methods to detect and isolate colibactin producing bacteria

Applicant: CSIC

Issue date: Pending

Patent No.: Trade Secret (ref.: 2203)

Title: Methods for long-term preservation of gut microbiota in viable conditions

Applicant:CSIC-MVT

Issue date: April 13, 2021

Patent No.: Trade mark

Title: GutAlive®

Applicant: Microviable Therapeutics

Issue date: January 23, 2018

Patent No.: Trade mark

Title: Microviable Therapeutics

Applicant: Microviable Therapeutics

Issue date: April 26, 2017

* All the disclosed IP has been licensed with exclusive rights to Microviable Therapeutics SL.

MICROVIABLE THERAPEUTICS

CONTACT US

CONTACT